AU2017277734B2 - New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
AU2017277734B2
AU2017277734B2 AU2017277734A AU2017277734A AU2017277734B2 AU 2017277734 B2 AU2017277734 B2 AU 2017277734B2 AU 2017277734 A AU2017277734 A AU 2017277734A AU 2017277734 A AU2017277734 A AU 2017277734A AU 2017277734 B2 AU2017277734 B2 AU 2017277734B2
Authority
AU
Australia
Prior art keywords
methyl
pyrimidin
group
pyrrolo
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017277734A
Other languages
English (en)
Other versions
AU2017277734A1 (en
Inventor
Maïa CHANRION
Didier DEMARLES
Olivier Geneste
Árpád KISS
András Kotschy
Elodie LEWKOWICZ
Alba Macias
Balázs MOLNÁR
James Brooke MURRAY
Attila Vasas
Csaba WÉBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Laboratoires Servier SAS
Publication of AU2017277734A1 publication Critical patent/AU2017277734A1/en
Application granted granted Critical
Publication of AU2017277734B2 publication Critical patent/AU2017277734B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2017277734A 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them Ceased AU2017277734B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655392 2016-06-10
FR1655392A FR3052452B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2017/064067 WO2017212012A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
AU2017277734A1 AU2017277734A1 (en) 2018-12-20
AU2017277734B2 true AU2017277734B2 (en) 2021-07-01

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277734A Ceased AU2017277734B2 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (46)

Country Link
US (1) US11046681B2 (enExample)
EP (1) EP3468974B1 (enExample)
JP (1) JP6928005B2 (enExample)
KR (1) KR20190016106A (enExample)
CN (1) CN109311888B (enExample)
AR (1) AR108706A1 (enExample)
AU (1) AU2017277734B2 (enExample)
BR (1) BR112018075433A2 (enExample)
CA (1) CA3027014C (enExample)
CL (1) CL2018003474A1 (enExample)
CO (1) CO2018013210A2 (enExample)
CR (1) CR20180564A (enExample)
CU (1) CU20180145A7 (enExample)
CY (1) CY1122870T1 (enExample)
DK (1) DK3468974T3 (enExample)
DO (1) DOP2018000270A (enExample)
EA (1) EA037211B1 (enExample)
EC (1) ECSP18090144A (enExample)
ES (1) ES2775789T3 (enExample)
FR (1) FR3052452B1 (enExample)
GE (1) GEP20207160B (enExample)
HR (1) HRP20200361T1 (enExample)
HU (1) HUE049507T2 (enExample)
IL (1) IL263463B (enExample)
LT (1) LT3468974T (enExample)
MA (1) MA45222B1 (enExample)
MD (1) MD3468974T2 (enExample)
ME (1) ME03670B (enExample)
MX (1) MX374794B (enExample)
MY (1) MY196562A (enExample)
NI (1) NI201800132A (enExample)
NZ (1) NZ748946A (enExample)
PE (1) PE20220567A1 (enExample)
PH (1) PH12018502515B1 (enExample)
PL (1) PL3468974T3 (enExample)
PT (1) PT3468974T (enExample)
RS (1) RS60029B1 (enExample)
RU (1) RU2743163C2 (enExample)
SG (1) SG11201810629QA (enExample)
SI (1) SI3468974T1 (enExample)
SV (1) SV2018005791A (enExample)
TN (1) TN2018000410A1 (enExample)
TW (1) TWI620750B (enExample)
UA (1) UA123794C2 (enExample)
UY (1) UY37288A (enExample)
WO (1) WO2017212012A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
NZ762994A (en) 2017-08-28 2025-11-28 Enanta Pharm Inc Hepatitis b antiviral agents
BR112020010547A2 (pt) 2017-11-29 2020-10-27 Les Laboratoires Servier derivados de piperidinila como inibidores de protease 7 específica de ubiquitina
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
AR116474A1 (es) 2018-09-21 2021-05-12 Enanta Pharm Inc DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
BR112021010644A2 (pt) * 2018-12-06 2021-09-28 Almac Discovery Limited Composto, estereoisômero, tautômero, hidrato, derivado de n-óxido ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratamento de obesidade, resistência a insulina, diabetes tipo ii, atrofia muscular e câncer e para redução de perda de massa muscular em um indivíduo, e, inibidor de usp19
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378807A (zh) * 2005-12-21 2009-03-04 先灵公司 H3拮抗剂/反相激动剂与食欲抑制剂的组合
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
SI3468971T1 (sl) * 2016-06-10 2020-07-31 Les Laboratoires Servier Novi derivati piperidinila, substituiranega s (hetero)arilom, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Also Published As

Publication number Publication date
RU2018147430A (ru) 2020-07-10
JP2019517556A (ja) 2019-06-24
HRP20200361T1 (hr) 2020-06-12
MY196562A (en) 2023-04-19
CO2018013210A2 (es) 2018-12-28
MA45222B1 (fr) 2020-04-30
CN109311888A (zh) 2019-02-05
BR112018075433A2 (pt) 2019-03-19
UY37288A (es) 2018-01-02
RS60029B1 (sr) 2020-04-30
SV2018005791A (es) 2019-01-16
CN109311888B (zh) 2021-09-14
MD3468974T2 (ro) 2020-05-31
EP3468974B1 (en) 2020-02-12
NI201800132A (es) 2019-04-08
WO2017212012A1 (en) 2017-12-14
CA3027014C (en) 2021-01-05
ME03670B (en) 2020-10-20
DOP2018000270A (es) 2019-05-15
US11046681B2 (en) 2021-06-29
SG11201810629QA (en) 2018-12-28
MX2018015216A (es) 2019-04-25
IL263463B (en) 2021-01-31
CA3027014A1 (en) 2017-12-14
LT3468974T (lt) 2020-04-10
EA201892838A1 (ru) 2019-06-28
FR3052452B1 (fr) 2018-06-22
ECSP18090144A (es) 2019-01-31
GEP20207160B (en) 2020-10-12
US20190144448A1 (en) 2019-05-16
RU2018147430A3 (enExample) 2020-07-10
PT3468974T (pt) 2020-03-25
IL263463A (en) 2019-01-31
ES2775789T3 (es) 2020-07-28
UA123794C2 (uk) 2021-06-02
CL2018003474A1 (es) 2019-05-24
NZ748946A (en) 2025-06-27
CY1122870T1 (el) 2021-05-05
KR20190016106A (ko) 2019-02-15
JP6928005B2 (ja) 2021-09-01
PL3468974T3 (pl) 2020-07-13
FR3052452A1 (enExample) 2017-12-15
EA037211B1 (ru) 2021-02-19
AU2017277734A1 (en) 2018-12-20
CU20180145A7 (es) 2019-07-04
MA45222A (fr) 2019-04-17
AR108706A1 (es) 2018-09-19
TW201802092A (zh) 2018-01-16
PH12018502515A1 (en) 2019-09-30
EP3468974A1 (en) 2019-04-17
MX374794B (es) 2025-03-06
RU2743163C2 (ru) 2021-02-15
TN2018000410A1 (en) 2020-06-15
TWI620750B (zh) 2018-04-11
PE20220567A1 (es) 2022-04-13
PH12018502515B1 (en) 2021-11-10
HUE049507T2 (hu) 2020-09-28
CR20180564A (es) 2019-03-04
DK3468974T3 (da) 2020-05-11
SI3468974T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
AU2017277734B2 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
AU2017277732B2 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
US10016438B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
KR102039764B1 (ko) 신규 티에노피리미딘 유도체, 그의 제조 방법 및 그의 치료 용도
AU2009212338A1 (en) Furo-and Thieno[3,2-c] Pyridines
CA3083320C (en) Piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
OA19084A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK40007201A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40007201B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40004049A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40034164A (en) New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
EA037563B1 (ru) Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)